Forma Therapeutics Holdings, Inc.
FMTXDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001538927
Forma Therapeutics Holdings, Inc. was delisted in 2022; its insiders filed their last Form 4 on Oct 14, 2022; 139 institutions reported holding it in 13F filings for Q3 2022, worth $836.5M in total; HHLR Advisors (Hillhouse) was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 139
- Q3 2022, +33 vs. previous quarter
- 13F value
- $835.0M
- Reported value at the end of Q3 2022
- Superinvestors holding
- 1
- At the end of Q3 2022
Superinvestors holding FMTX, Q3 2022
1 superinvestor reports holding Forma Therapeutics Holdings, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
HHLR Advisors (Hillhouse)
Zhang Lei
0.6%
Forma Therapeutics Holdings, Inc.'s share of the portfolio
- Shares
- 1,100,000
- Value
- $21.9M
Latest insider trades
Open-market purchases and sales by Forma Therapeutics Holdings, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Cook David NSVP, Chief Scientific Officer | SSale | −3.53K | $9.78 | −$34.5K | −17.7%16.5K after | |
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Lee Frank D.President and CEO | SSale | −18.0K | $9.78 | −$175.9K | −18.4%79.8K after | |
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Kelly Patrick F.SVP, Chief Medical Officer | SSale | −5.25K | $9.78 | −$51.3K | −7.5%64.9K after | |
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Shegog ToddSVP, Chief Financial Officer | SSale | −5.69K | $9.78 | −$55.6K | −20.0%22.8K after | |
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Lesser Brian AndrewSVP, Commercial | SSale | −3.84K | $9.78 | −$37.5K | −17.9%17.6K after | |
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Wadlinger Mary E.See Remarks | SSale | −4.68K | $9.78 | −$45.8K | −3.4%134.5K after | |
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Potts JeannetteSee Remarks | SSale | −4.67K | $9.78 | −$45.7K | −17.3%22.4K after |
Top 10 13F holders, Q3 2022
The largest institutional positions in Forma Therapeutics Holdings, Inc. at the end of Q3 2022; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 9,011,651 | $179.8M | 3.84% | 00.0% | Unchanged |
| BlackRock Inc. | 3,632,271 | $72.5M | 0.00% | +513,211+16.5% | Added |
| Baker Bros. Advisors LP | 1,886,760 | $37.6M | 0.25% | −138,116−6.8% | Reduced |
| Vanguard Group Inc | 1,865,281 | $37.2M | 0.00% | +220,012+13.4% | Added |
| TIG Advisors, LLC | 1,305,794 | $26.1M | 0.99% | +1,305,794 | New |
| Water Island Capital LLC | 1,253,785 | $25.0M | 1.42% | +1,253,785 | New |
| Alpine Associates Management Inc. | 1,140,500 | $22.8M | 0.95% | +1,140,500 | New |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 1,100,000 | $21.9M | 0.58% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 1,065,413 | $21.3M | 4.96% | −500,113−31.9% | Reduced |
| Vivaldi Asset Management, LLC | 1,029,333 | $20.5M | 0.97% | +1,029,333 | New |